RecruitingPhase 2Phase 3NCT05674552

Exogenous Ketone Esters for Refractory Status Epileptics

Efficacy of Exogenous Ketone Esters for Children With Refractory Convulsive Status Epileptics

Sponsor

Sohag University

Enrollment

50 participants

Start Date

Jan 10, 2023

Study Type

INTERVENTIONAL

Conditions

Status Epilepticus

Summary

This study aims to investigate the efficacy of add-on exogenous ketone esters for the treatment of children with refractory generalized convulsive status epilepticus

Eligibility

Min Age: 1 YearMax Age: 10 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Exogenous ketone ester for people with status epilepticus. The study is currently recruiting participants at 1 location. People eligible for this study include aged 1 Year to 10 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGExogenous ketone ester

500 mg/kg over 5 min administered by nasogastric tube, followed after 1 hr by repeated hourly doses of 125 mg/kg for 8 hrs.

Locations(1)

Department of Pediatrics at Sohag University Hospital

Sohag, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05674552

Related Trials

Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)

NCT0690717352 locations

EEG Monitoring for Refractory Status Epilepticus

NCT041704911 location